GPC Biotech To Cut 38 Percent Of Workforce
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.
You may also be interested in...
GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.
GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.
More Satraplatin Pain For GPC As Other Shoe Drops
Celgene backs out of overseas deal for failed prostate-cancer chemo.